Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2011

View Archived Issues

Yale University scientists synthesize the aglycon of lomaiviticin A, a promising anticancer agent

Acacia Pharma completes phase I APD-515 trial for xerostomia in advanced cancer

Medivir begins phase Ia trial of HCV polymerase inhibitor TMC-649128

Bombesin BB2 receptor antagonist 77427 shows promise in preclinical models of asthma

Gap junction alpha-1 protein is a marker of prognosis in prostate cancer

First-in-class antibiotic RNPA-1000 inhibits bacterial turnover of RNA

Genotype of polymorphic SLC6A4 gene variants modulates effects of cocaine in vitro

Endoribonuclease Dicer is a potential target for geographic atrophy

New neuraminidase inhibitors claimed at University of British Columbia

AtheroNova advances preclinical evaluation of agents for atherosclerosis

Astellas Pharma withdraws MAA for darexaban in Japan

Adventrx to acquire SynthRx and purified poloxamer-188 for sickle cell disease

SYGNIS Pharma licenses European patent rights to AX-200

Crofelemer is safe and efficacious in phase II trial in adults with watery diarrhea

Lymphoseek phase III trial in breast cancer and melanoma reaches accrual objective

Australian scientists claim novel inhibitors of neuraminidase

Apricus licenses Vitaros to Neopharm in Israel and Palestinian territories

Alkermes reports phase II data on ALKS-37 in opioid-induced bowel dysfunction

Lundbeck donates certain rights regarding Lu-AE58479 to NINDS

New inhibitors claimed of MEKK 5

FDA accepts Acurox NDA filing and grants priority review

Sanofi-aventis to acquire Genzyme

Treatment begins in phase III trial of rHuPH20-delivered MabThera in NHL

FDA requests additional development activities to support approval of Adventrx's ANX-514

Raptor Pharma reopens enrollment in phase III DR Cysteamine trial in nephropathic cystinosis

Popular Stories

University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Beijing Innocare Pharma Tech discloses new GSPT1 degradation inducers
BioWorld Science
Beijing Innocare Pharma Tech Co. Ltd. has synthesized new antibody-drug conjugates comprising antibody or antigen-binding fragment covalently linked to eukaryotic...